-+ 0.00%
-+ 0.00%
-+ 0.00%

AMBROS THERAPEUTICS LAUNCHES WITH $125 MILLION SERIES A FINANCING TO ADVANCE NERIDRONATE THROUGH PHASE 3 REGISTRATIONAL PROGRAM FOR COMPLEX REGIONAL PAIN SYNDROME TYPE 1

Reuters·12/16/2025 13:06:08

Please log in to view news